Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Recurrence 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Bortezomib 20Blood Specimen Collection 9Surveys and Questionnaires 8Lenalidomide 8Dexamethasone 8pomalidomide 6daratumumab 6Flow Cytometry 6Immunoenzyme Techniques 5Biopsy 5plerixafor 4idecabtagene vicleucel 4carfilzomib 4Standard of Care 4Polymerase Chain Reaction 4Amplified Fragment Length Polymorphism Analysis 4Specimen Handling 3Psychiatric Rehabilitation 3Patient Reported Outcome Measures 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Interviews as Topic 3Drug Therapy 3Data Collection 3Cytogenetic Analysis 3Chromatin Immunoprecipitation Sequencing 3talquetamab 2selinexor 2belantamab mafodotin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × fluoroazomycin arabinoside × Plasma cell × Clear all
NCT04409314 2023-08-21

Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy

University of California, San Francisco

Completed
23 enrolled
LymphoidPlasma cell

Multiple Myeloma, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡